Article
Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy, revealed the results of its annual Physician Satisfaction Survey today.
Diplomat Specialty Pharmacy, the nation’s largest privately held specialty pharmacy, revealed the results of its annual Physician Satisfaction Survey today. The survey, conducted by Gartner & Associates LLC in July 2012, reaffirms Diplomat’s industry leading physician satisfaction rates.
Key survey findings reflect:
• 98% of healthcare respondents are satisfied overall with Diplomat
• 99% indicated that Diplomat meets their expectations
• 91% indicated that Diplomat exceeds the service levels of other pharmacies
Further, there was a 10% increase over 2011 in the number of healthcare workers who responded “very satisfied” when asked to rank their satisfaction based on the knowledge and helpfulness of Diplomat’s care staff, pharmacists and nurses.
Diplomat Specialty Pharmacy CEO, Phil Hagerman, says the overwhelmingly positive 2012 survey results affirm the daily efforts of the company’s Education & Training center known as Diplomat University. “This type of physician-provided data reinforces the importance and value of our approach to employee training and education,” notes Hagerman. “Our increases in service levels are compelling and demonstrate that we are not putting growth in front of patient services and overall care. We believe that our industry-leading Diplomat University is helping to create a more knowledgeable, helpful and compassionate team of support staff.”
The company also announced today that they have entered into a 5-year $60 million revolving line of credit and commercial banking relationship with GE Capital, JP Morgan Chase and Comerica. This new line of credit replaces Diplomat’s prior credit facility of $30 million.
“This new expanded line of credit is a significant milestone for Diplomat and provides us with additional access to capital to support our strategic growth initiatives,” said Phil Hagerman, Diplomat’s CEO.
SOURCE: Diplomat Specialty Pharmacy
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa